Biotech in Bangalore - reflections on a decade of debate


Published on

by Ian Scoones, STEPS co-director

Published in: Education, Technology, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • .
  • .
  • Biotech in Bangalore - reflections on a decade of debate

    1. 1. Biotechnology in Bangalore Reflections on a decade of debate Ian Scoones STEPS Centre, Institute of Development Studies, University of Sussex, UK  
    2. 2. Bangalore: ‘the knowledge economy capital’
    3. 3. 2002: hype and hope <ul><li>Rapid economic growth and technology-led industrialisation (notably IT sector) </li></ul><ul><li>Competition between Indian states – and Chief Ministers - for foreign investment </li></ul><ul><li>Bangalore pitched as a ‘knowledge hub’ for biotechnology, linking public and private science </li></ul><ul><li>Substantial political (and economic) backing from State government (Vision Group, policy etc.) </li></ul>
    4. 4. Policy narratives <ul><li>From IT to BT …. State support for new investments in biotech industry (mostly small start-ups doing contract research for US/European biotech companies) </li></ul><ul><li>From the Green Revolution to the Gene Revolution…. GM crops (Bt cotton) to help solve the cost constraint problems of agriculture. Joint public-private efforts, including State Ag University, Monsanto etc. </li></ul>
    5. 5. Bangalore and biotech
    6. 6. Examples R and D focus R and D Interactions Elite science IISc, NCBS Basic biology US/European universities Public science UAS Tissue culture, some transgenics Contract research for Monsanto Start up companies Avesthagen,Metahelix, Strand Genomics Genomic databases for Marker Assisted Selection Contract research for seed companies, Monsanto etc. Established local bio/agri- companies Rallis, Biocon Transgenics; seed development; genomics platforms Internal R and D; limited joint research TNCs Monsanto Transgenics; Pest management and cotton Internal company interactions; contracting out
    7. 7. Innovation and development <ul><li>Excellence model </li></ul><ul><li>Cluster and hub model </li></ul><ul><li>Public private partnerships model </li></ul>
    8. 8. <ul><li>2002-12 - Six challenges to the vision </li></ul>
    9. 9. Science <ul><li>New developments (genomics/informatics), </li></ul><ul><li>Transgenics hurdles </li></ul><ul><li>Few big-hit patents </li></ul><ul><li>Revised science-business model </li></ul>
    10. 10. Business <ul><li>From start-up to emergent majors, through global alliances </li></ul>
    11. 11. 2003-04 2010-11 Serum Institute Biocon Biocon Serum Institute Panacea Biotec Panacea Biotec Novo Nordisk Nuziveedu Seeds Venkateshwara Hatcheries Reliance Life Sciences Bharat Serums Quintiles India Aventis Pharma NovoNordisk Eli Lilly Co Rasi Seeds Chiron Behring Vaccines Mayhco GSK Transasia Indian Immunologicals Ankur Seeds Mayhco Monsanto Syngene International Novozymes Bharat Biotech Shanta biotechnics Indian Immunologicals Wockhardt Krishidan Seeds
    12. 13. Politics <ul><li>The state and economic development. </li></ul><ul><li>The diminishing influence of the biotech-science elite? </li></ul>
    13. 14. Poverty and development <ul><li>Bt cotton spread, but who benefits? </li></ul><ul><li>Inequalities in the new (bio)economy </li></ul><ul><li>Inclusive innovation </li></ul>
    14. 15. Civil society action <ul><li>Public action and protest </li></ul><ul><li>Public interest litigation, court cases and media </li></ul>
    15. 16. Regulation <ul><li>Risk, uncertainty and public disquiet </li></ul><ul><li>An acceptance of a more </li></ul><ul><li>precautionary stance? </li></ul>
    16. 18. The future? 4 issues.... <ul><li>Beyond transgenics </li></ul><ul><li>The Mysore model and state capitalism </li></ul><ul><li>Inclusive innovation – S and T for development </li></ul><ul><li>Publics, precaution and regulation </li></ul>